Publication
Insulin-Like Growth Factor Axis and Survival in Metastatic Hormone-Sensitive Prostate Cancer: Post-Hoc Analysis From the ENZAMET Phase 3 Trial.
Michael A Cilento, Hui-Ming Lin, Nicole Yeung, Rachel M N Kim, Neil Portman, Martin R Stockler, Andrew J Martin, Vinod Subhash, Sonia Yip, Lisa M Butler, Ian C Marschner, Peter J Meikle, Arun A Azad, Ian D Davis, Lisa G Horvath, Christopher J Sweeney
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: A higher ratio of IGF-1:IGF binding protein 1 (IGFBP1) was associated with improved prognosis in the CHAARTED trial of docetaxel in participants with metastatic hormone-sensitive prostate cancer (mHSPC). The ENZAMET trial demonstrated the survival benefit of adding enzalutamide to…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Prostate Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available